Morgan Stanley lowered the firm’s price target on Prime Medicine to $18 from $19 and keeps an Equal Weight rating on the shares after earnings. Prime remains on track to complete the company’s first IND filing as early as 2024 and will present preclinical data highlighting the potential of the PASSIGE platform to multiplex edit CAR-T cells on December 11 at ASH, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRME:
- Prime Medicine files $500M mixed securities shelf
- Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Prime Medicine reports Q3 EPS (55c), consensus (46c)
- Prime Medicine presents prime editing data in primates for GSD1b
- Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b